Not attending the IPA World Congress + Probiota? View ADM Postbiotics comprehensive solutions for all

Overview


ADM PROBI

New research continues to emerge, demonstrating the positive impact that can come from postbiotics. From supporting metabolic and digestive health to benefits for mood, sleep, and cognitive function, they have been gaining interest for their effectiveness in addressing a wide range of consumer wants and needs.

With three clinically backed postbiotic products—ES1, BPL1™, and L. gasseri CP2305—plus the formulation flexibility to adapt to individual customer needs, ADM is your single trusted source for clinically studied and effective postbiotics. Each of our ingredients is backed by gold-standard clinical trials to ensure efficacy and optimal performance in your finished products. Our heat-treating method never changes, so you get batch-to-batch consistency, and we have the only facility in the world that manufactures both probiotics and postbiotics simultaneously.

ADM unlocks the power of nature to enrich life for people and pets through science, innovation, and partnership. As a global leader in human and animal nutrition, ADM delivers trusted, nature-based solutions that support health and well-being from the inside out.

Their growing microbiome portfolio spans prebiotics, probiotics, postbiotics, phages, & enzymes — backed by clinical research and powered by advanced biotechnology — helping consumers around the world live healthier, more balanced lives.

With deep expertise across fermentation, formulation, and global supply, ADM is pioneering the future of microbiome innovation while building a more resilient, sustainable food system.

This content is provided by ADM, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now


Latest Content

Related Resources

Co-create the support products GLP-1 users want

Co-create the support products GLP-1 users want

Content provided by ADM

White Paper

A proprietary survey of over 1,500 consumers taking anti-obesity medications found that 81% are willing to pay a premium for food and beverage products that provide added health benefits supportive of GLP-1 users.

Supplier Info Centre

ADM.png

For more product information visit ADM.